We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Qiagen's QIAsure Test to Determine Cervical Cancer Risks
Read MoreHide Full Article
Qiagen N V (QGEN - Free Report) recently started simultaneous launch of its QIAsure Methylation molecular diagnostic test in Europe, Middle East and Africa. Notably, this CE-IVD marked assay helps in determining individual patient’s risk of developing cervical cancer.
Interestingly, the launch of this unique screening test is a complimentary addition to Qiagen’s leading franchise of Human Papillomavirus (HPV) testing. In particular, this test will stratify patients in terms of how much risk she bears of developing cervical cancer; so that appropriate surveillance and treatment decisions can be carried out.
Tests for Cervical Cancer
Globally, cervical cancer affects more than 500,000 women annually and as per estimates by the American Cancer Society, this disease is likely to claim almost 4,120 lives in 2016. Although cervical cancer is caused by HPV, a woman with a positive HPV test result does not necessarily have cervical cancer.
Thus, to find out whether the HPV-infected cervical cells of a woman have transformed into cervical cancer cells, a follow-up test is required to differentiate an individual patient’s risk of developing the disease. Currently, cytology is the standard screening assay for this purpose. However, cytology is not an appropriate test for this purpose as it lacks sensitivity in individual detection.
QIAsure accurately stratifies cervical cancer risk and is thus the most sought after assay, which offers highly sensitive and specific results for patients and clinicians. This test is believed to bring revolutionary improvement in women’s health, offering reliable risk stratification as a follow-up to HPV screening or cytology.
Our Take
In the last reported quarter, Qiagen witnessed a slight slow down in its overseas revenues for HPV test. We believe that the company’s plan to make the QIAsure test available in the European market in the later half of 2016 will boost its HPV test revenues.
With the increasing use of cervical cancer diagnostic tests such as pap smear tests, HPV testing and colposcopy for early detection, the global cervical cancer diagnostic market has become highly competitive. Currently, this market is expected to grow at a CAGR of 2%--5% during 2015 to 2020 and we expect the QIAsure launch to allow Qiagen to capture a larger share of this market.
Zacks Rank & Key Picks
The stock currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks are Baxter International Inc. (BAX - Free Report) , NuVasive, Inc. and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Baxter sports a Zacks Rank #1 (Strong Buy), NuVasive and LeMaitre carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Qiagen's QIAsure Test to Determine Cervical Cancer Risks
Qiagen N V (QGEN - Free Report) recently started simultaneous launch of its QIAsure Methylation molecular diagnostic test in Europe, Middle East and Africa. Notably, this CE-IVD marked assay helps in determining individual patient’s risk of developing cervical cancer.
Interestingly, the launch of this unique screening test is a complimentary addition to Qiagen’s leading franchise of Human Papillomavirus (HPV) testing. In particular, this test will stratify patients in terms of how much risk she bears of developing cervical cancer; so that appropriate surveillance and treatment decisions can be carried out.
Tests for Cervical Cancer
Globally, cervical cancer affects more than 500,000 women annually and as per estimates by the American Cancer Society, this disease is likely to claim almost 4,120 lives in 2016. Although cervical cancer is caused by HPV, a woman with a positive HPV test result does not necessarily have cervical cancer.
Thus, to find out whether the HPV-infected cervical cells of a woman have transformed into cervical cancer cells, a follow-up test is required to differentiate an individual patient’s risk of developing the disease. Currently, cytology is the standard screening assay for this purpose. However, cytology is not an appropriate test for this purpose as it lacks sensitivity in individual detection.
QIAsure accurately stratifies cervical cancer risk and is thus the most sought after assay, which offers highly sensitive and specific results for patients and clinicians. This test is believed to bring revolutionary improvement in women’s health, offering reliable risk stratification as a follow-up to HPV screening or cytology.
Our Take
In the last reported quarter, Qiagen witnessed a slight slow down in its overseas revenues for HPV test. We believe that the company’s plan to make the QIAsure test available in the European market in the later half of 2016 will boost its HPV test revenues.
With the increasing use of cervical cancer diagnostic tests such as pap smear tests, HPV testing and colposcopy for early detection, the global cervical cancer diagnostic market has become highly competitive. Currently, this market is expected to grow at a CAGR of 2%--5% during 2015 to 2020 and we expect the QIAsure launch to allow Qiagen to capture a larger share of this market.
Zacks Rank & Key Picks
The stock currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks are Baxter International Inc. (BAX - Free Report) , NuVasive, Inc. and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Baxter sports a Zacks Rank #1 (Strong Buy), NuVasive and LeMaitre carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>